GreenLight SPAC Presentation Deck

Nine projected product launches and multiple clinical milestones through 2026 Acquisitions and in-licensing deals have potential to further boost pipeline from GreenLight's engine GreenLight's cumulative TAM Colorado Potato Beetle Varroa Mite Botrytis Diamondback Moth Fusarium Powdery Mildew Two Spotted Spider Mite Covid Vaccine Seasonal Flu Supra-seasonal Flu Antibody therapy SCD Gene Therapy 2021 2022 $350M P1 Launch P2/P3 P1 2023 ~$33B 6 more agricultural programs planned for 2027 and beyond Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Launch 2024 ~$34B P2/P3 Launch P1 : EPA submission P1 P2/P3 : Clinical phase P1 2025 ~$40B Launch Launch Launch Launch P1 Partnership milestone 2026 O -$41B Launch Launch 13

View entire presentation